Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;36(3):e14531.
doi: 10.1111/ctr.14531. Epub 2021 Nov 29.

Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States

Geeta Karadkhele  1 , Charlotte Duneton  1   2 , Rouba Garro  3 , Idelberto Raul Badell  1 , Thomas C Pearson  1 , Christian P Larsen  1 , Julien Hogan  1   2
Affiliations

Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States

Geeta Karadkhele et al. Clin Transplant. 2022 Mar.

Abstract

The adoption of de novo belatacept in kidney transplant (kTx) recipients was hampered by an increased risk of acute cellular rejection (ACR) with variation in adopted belatacept based immunosuppressive therapies across centers. We used data from the Scientific Registry of Transplant Recipients (SRTR) to evaluate the temporal trends in belatacept use and describe the associated induction and maintenance regimens in US adult kTx recipients transplanted between June 2011 and December 2018. The number of patients receiving de novo-belatacept based immunosuppressive therapy increased from .74% in 2011 to 3.11% in 2016. In 2016, 66/207 centers used de novo belatacept-based regimen with 3.03% using it in over 50% of their patients. The use of T-cell depleting agents increased with time. Since 2012, the rate of calcineurin inhibitor (CNI) use in combination with belatacept remained stable around 50% and ∼30% remained under belatacept/CNI combination at 1-year post-transplantation. The adoption of belatacept as de novo immunosuppressive regimen has been slow and its use remains low in the United States. Various regimens have been used to modulate the risk of ACR. Further studies evaluating the long-term outcomes of these regimens and assessing their safety especially with regard to the risk of infection are needed.

Keywords: Scientific Registry for Transplant Recipients (SRTR); costimulation; epidemiology; fusion proteins and monoclonal antibodies: belatacept; immunosuppressant; immunosuppressive regimen; induction.

PubMed Disclaimer

References

REFERENCES

    1. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443-453. http://doi.org/10.1111/j.1600-6143.2005.00749.x.
    1. Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018;18(7):1783-1789. http://doi.org/10.1111/ajt.14721.
    1. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-546. http://doi.org/10.1111/j.1600-6143.2009.03005.x.
    1. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547-557. http://doi.org/10.1111/j.1600-6143.2010.03016.x.
    1. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(4):333-343. http://doi.org/10.1056/NEJMoa1506027.

Publication types

LinkOut - more resources